Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.

PURPOSE Because lactate accumulation is considered a surrogate for hypoxia and tumor radiation resistance, we studied the spatial distribution of the lactate-to-N-acetyl-aspartate ratio (LNR) before radiation therapy (RT) with 3D proton magnetic resonance spectroscopic imaging (3D-(1)H-MRSI) and assessed its impact on local tumor control in glioblastoma (GBM). METHODS AND MATERIALS Fourteen patients with newly diagnosed GBM included in a phase 2 chemoradiation therapy trial constituted our database. Magnetic resonance imaging (MRI) and MRSI data before RT were evaluated and correlated to MRI data at relapse. The optimal threshold for tumor-associated LNR was determined with receiver-operating-characteristic (ROC) curve analysis of the pre-RT LNR values and MRI characteristics of the tumor. This threshold was used to segment pre-RT normalized LNR maps. Two spatial analyses were performed: (1) a pre-RT volumetric comparison of abnormal LNR areas with regions of MRI-defined lesions and a choline (Cho)-to- N-acetyl-aspartate (NAA) ratio ≥ 2 (CNR2); and (2) a voxel-by-voxel spatial analysis of 4,186,185 voxels with the intention of evaluating whether pre-RT abnormal LNR areas were predictive of the site of local recurrence. RESULTS A LNR of ≥ 0.4 (LNR-0.4) discriminated between tumor-associated and normal LNR values with 88.8% sensitivity and 97.6% specificity. LNR-0.4 voxels were spatially different from those of MRI-defined lesions, representing 44% of contrast enhancement, 64% of central necrosis, and 26% of fluid-attenuated inversion recovery (FLAIR) abnormality volumes before RT. They extended beyond the overlap with CNR2 for most patients (median: 20 cm(3); range: 6-49 cm(3)). LNR-0.4 voxels were significantly predictive of local recurrence, regarded as contrast enhancement at relapse: 71% of voxels with a LNR-0.4 before RT were contrast enhanced at relapse versus 10% of voxels with a normal LNR (P<.01). CONCLUSIONS Pre-RT LNR-0.4 in GBM indicates tumor areas that are likely to relapse. Further investigations are needed to confirm lactate imaging as a tool to define additional biological target volumes for dose painting.

[1]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[2]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[3]  Fred L. Drake,et al.  The Python Language Reference Manual , 1999 .

[4]  Guido van Rossum,et al.  The Python language reference manual: for Python version 3.2 , 2011 .

[5]  Douglas L. Arnold,et al.  Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma , 2008, Journal of Neuro-Oncology.

[6]  Susan M. Chang,et al.  Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas in vivo. , 2005, AJNR. American journal of neuroradiology.

[7]  C. Toulas,et al.  Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme. , 2007, International journal of radiation oncology, biology, physics.

[8]  Xavier Franceries,et al.  Plate-based transfection and culturing technique for genetic manipulation of Plasmodium falciparum , 2012, Malaria Journal.

[9]  B. Jones,et al.  Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. , 2013, The British journal of radiology.

[10]  K. Wallner,et al.  Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. , 1989, International journal of radiation oncology, biology, physics.

[11]  A. Bergenheim,et al.  Glucose metabolites, glutamate and glycerol in malignant glioma tumours during radiotherapy , 2008, Journal of Neuro-Oncology.

[12]  Herbert J. Carlin,et al.  Network theory , 1964 .

[13]  S. Nelson,et al.  Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[14]  M. Berger,et al.  Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. , 2002, Journal of neurosurgery.

[15]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.

[16]  Susan M. Chang,et al.  Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy , 2008, Journal of Neuro-Oncology.

[17]  J. Walecki,et al.  1H-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. , 2002, International journal of radiation oncology, biology, physics.

[18]  Ilwoo Park,et al.  Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. , 2007, International journal of radiation oncology, biology, physics.

[19]  Julien Verrax,et al.  Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. , 2008, The Journal of clinical investigation.

[20]  S Cerdán,et al.  Mapping extracellular pH in rat brain gliomas in vivo by 1H magnetic resonance spectroscopic imaging: comparison with maps of metabolites. , 2001, Cancer research.

[21]  Inas S. Khayal,et al.  Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM , 2009, Journal of Neuro-Oncology.

[22]  Susan M. Chang,et al.  Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging. , 2013, Neuro-oncology.

[23]  Jinsong Wu,et al.  The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas , 2012, Acta Neurochirurgica.

[24]  C. Toulas,et al.  αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma. , 2013, European journal of cancer.

[25]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[26]  Mitchel S Berger,et al.  3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. , 2004, International journal of radiation oncology, biology, physics.

[27]  Vincent Gregoire,et al.  Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. , 2011, Seminars in radiation oncology.

[28]  Isabelle Berry,et al.  Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. , 2008, International journal of radiation oncology, biology, physics.

[29]  M. Dewhirst,et al.  One-stop-shop tumor imaging: buy hypoxia, get lactate free. , 2008, The Journal of clinical investigation.

[30]  R. Kreis Issues of spectral quality in clinical 1H‐magnetic resonance spectroscopy and a gallery of artifacts , 2004, NMR in biomedicine.